Skip Over Navigation Links

PGRN Network-wide Publications

PharmGKB summary: very important pharmacogene information for CYP2B6
Thorn CF., Lamba JK, Lamba V, Klein TE, Altman RB.
Pharmacogenet. Genomics. 2010 Aug; 20(8):520-3.

Clopidogrel pathway
Sangkuhl K, Klein TE, Altman RB.
Pharmacogenet. Genomics. 2010 Jul;20(7):463-5.

Very important pharmacogene summary: thiopurine S-methyltransferase.
Wang L, Pelleymounter L, Weinshilboum R, Johnson JA, Hebert JM, Altman RB, Klein TE
Pharmacogenet. Genomics. 2010 Jun;20(6):401-5.

Vascular endothelial growth factor pathway.
Maitland ML, Lou XJ, Ramirez J, Desai AA, Berlin DS, McLeod HL, Weichselbaum RR, Ratain MJ, Altman RB, Klein TE.
Pharmacogenet. Genomics. 2010 May;20(5):346-9.

Cytochrome P450 2C9-CYP2C9.
Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE, Altman RB
Pharmacogenet. Genomics. 2010 Apr;20(4):277-81.

Lessons learned from the Fifth Statistical Analysis Workshop of the Pharmacogenetics Research Network
Elizabeth J. Atkinson, Shannon K. McDonnell, John S. Witte, Dana C. Crawford, Yiping Fan, Brooke Fridley, Dalin Li, Lang Li, Andrei Rodin, Wolfgang Sadee, Terry Speed, Scott T. Weiss, Jun Yang, Laura Yerges, Daniel J. Schaid
Pharmacogenomics. 2010 Mar, 11(3): 297-303

The Great Debate: Genome wide association studies in Pharmacogenetics Research, Good or Bad?
Kent R. Bailey, Cheng Cheng.
Pharmacogenomics. 2010 Mar, 11(3): 305-308

Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).
Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, Altman RB.
Pharmacogenet. Genomics. 2010 Mar 5.

KCNH2 pharmacogenomics summary.
Oshiro C, Thorn CF, Roden DM, Klein TE, Altman RB.
Pharmacogenet. Genomics. 2010 Feb 10.

Very important pharmacogene summary ADRB2.
Litonjua AA, Gong L, Duan QL, Shin J, Moore MJ, Weiss ST, Johnson JA, Klein TE, Altman RB.
Pharmacogenet. Genomics. 2010 Jan;20(1):64-9.

PharmGKB: very important pharmacogene - HMGCR.
Medina MW, Sangkuhl K, Klein TE, Altman RB.
Pharmacogenet. Genomics. 2010 Jan 15.

Taxane pathway
Oshiro, Connie; Marsh, Sharon; McLeod, Howard; Carrillo, Michelle Whirl; Klein, Teri; Altman, Russ
Pharmacogenet. Genomics. 2009 Dec; 19(12): 979-983

Bisphosphonates pathway.
Gong L, Altman RB, Klein TE.
Pharmacogenet. Genomics. 2009 Dec 16

PharmGKB very important pharmacogene: SLCO1B1.
Oshiro C, Mangravite L, Klein T, Altman R.
Pharmacogenet. Genomics. 2009 Nov 27

Thiopurine pathway.
Zaza G, Cheok M, Krynetskaia N, Thorn C, Stocco G, Hebert JM, McLeod H, Weinshilboum RM, Relling MV, Evans WE, Klein TE, Altman RB.
Pharmacogenet. Genomics. 2009 Nov 27

VKORC1 Pharmacogenomics Summary.
Owen RP, Gong L, Sagrieya H, Klein TE, Altman RB.
Pharmacogenet. Genomics. 2009 Nov 24

PharmGKB summary: very important pharmacogene information for angiotensin-converting enzyme.
Thorn CF, Klein TE, Altman RB.
Pharmacogenet. Genomics. 2009 Nov 5.

How will GINA influence participation in pharmacogenomics research and clinical testing?
Lynn Dressler and Sharon Terry.
Clinical Pharmacology and Therapeutics. 2009 Nov;86(5):472-5

Selective serotonin reuptake inhibitors pathway
Sangkuhl K, Klein TE, Altman RB.
Pharmacogenet. Genomics. 2009 Sep 8.

Clinically Available Pharmacogenomics Tests
DA Flockhart, T Skaar, DS Berlin, TE Klein and AT Nguyen
Clinical Pharmacology and Therapeutics. 2009 Jul;86(1):109-13

Pathways & VIP genes: Platinum pathway.
Marsh S, McLeod H, Dolan E, Shukla SJ, Rabik CA, Gong L, Hernandez- Boussard T, Lou XJ, Klein TE, Altman RB.
Pharmacogenet. Genomics. 2009 Jul;19(7):563-564.

Cytochrome P450 2D6 (VIP)
Owen RP, Sangkuhl K, Klein TE, Altman RB.
Pharmacogenet. Genomics. 2009 Jul;19(7):559-62.

Etoposide pathway.
Yang J, Bogni A, Schuetz EG, Ratain M, Eileen Dolan M, McLeod H, Gong L, Thorn C, Relling MV, Klein TE, Altman RB.
Pharmacogenet Genomics. 2009 Jul;19(7):552-553.

Codeine and morphine pathway.
Thorn CF, Klein TE, Altman RB.
Pharmacogenet. Genomics. 2009 Jul;19(7):556-8.

Antiestrogen pathway (aromatase inhibitor).
Desta Z, Nguyen A, Flockhart D, Skaar T, Fletcher R, Weinshilboum R, Berlin DS, Klein TE, Altman RB.
Pharmacogenet. Genomics. 2009 Jul;19(7):554-555.

Very important pharmacogene summary: sulfotransferase 1A1.
Hildebrandt M, Adjei A, Weinshilboum R, Johnson JA, Berlin DS, Klein TE, Altman RB.
Pharmacogenet. Genomics.2009 Jun;19(6):404-6.

Methods for analysis in pharmacogenomics: Lessons from the Pharmacogenetics Research Network (PGRN) Analysis Group
Srinivasan, Chen, Cheng, Conti, Duan, Fridley, Gu, Haines, Jorgenson, Kraja, Lasky-Su, Li, Rodin, Wang, Province and Ritchie
Pharmacogenomics. 2009 Feb;10(2):243-51

Pharmacogenomic Discovery Using Cell-Based Models
M Welsh, L Mangravite, M Wong M, K Tantisira, RS Huang, H McLeod & ME Dolan
Pharmacological Reviews. 2009, 4: 413-429

Economic Evaluation of Pharmacogenetic Tests.
A Wu, and AL Fuhlbrigge.
Clinical Pharmacology Therapeutics. 2008 Aug;84(2):272-4.

Creating and evaluating genetic tests predictive of drug response.
Weiss, McLeod, Flockhart, Dolan, Benowitz, Johnson, Ratain and Giacomini,
Nature Reviews Drug Discovery. 2008 Jul; 7(7):568-74.

Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.
Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, Giacomini KM, Krauss RM.
Nat Rev Drug Discov.2007 Nov;6(11):904-16.
Review. Erratum in: Nat Rev Drug Discov. 2008 Feb;7(2):185.

PharmGKB: Understanding the effects of individual genetic variants.
K Sangkuhl, DS Berlin, RB Altman, and TE Klein
Drug Metabolism Reviews. 2008 40:4,539-551

Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing.
Altman RB, Benowitz N, Gurwitz D, Lunshof J, Relling M, Lamba J, Wieben E, Mooney S, Giacomini K, Weiss S, Johnson JA, McLeod H, Flockhart D, Weinshilboum R, Shuldiner AR, Roden D, Krauss RM, Ratain M.
Pharmacogenomics. 2007 May;8(5):519.

When good drugs go bad.
Giacomini KM, Krauss RM, Roden DM, Eichelbaum M, Hayden MR, Nakamura Y.
Nature. 2007 Apr 26;446(7139):975-7.

The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response
K.M. Giacomini, C.M. Brett, R.B. Altman, N.L. Benowitz, E.M. Dolan, D.A. Flockhart, J.A. Johnson, R.M. Krauss, D.L. Kroetz, H.L. McLeod, M.J. Ratain, M.V. Relling, D.M. Roden, C.A. Schaefer, A.R. Shuldiner, T. Skaar, R.F. Tyndale, L. Wang, R.M. Weinshilboum, S.T. Weiss, I. Zineh
Clin Pharmacol Ther. 2007 Mar;81(3):328-45

Pharmacogenomics: Challenges and Opportunities
D.M. Roden, R.B. Altman, N.L. Benowitz, D.A. Flockhart, K.M. Giacomini, J.A. Johnson, R.M. Krauss, H.L. McLeod, M.J. Ratain, M.V. Relling, H.Z. Ring, A.R. Shuldiner, R.M. Weinshilboum, S.T. Weiss
Ann Intern Med. 2006 Nov 21;145(10):749-57

Comment Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism.
Mary V Relling, Russ B Altman, Matthew P Goetz, William E Evans
Lancet Oncology. epub

Genome-wide association studies in pharmacogenomics: Successes and lessons so far.
Alison A. Motsinger-Reif, Eric Jorgenson, Mary V. Relling, Deanna L. Kroetz, Richard Weinshilboum, Nancy J. Cox, Dan M. Roden
Pharmacogenetics and Genomics. under revision

This page last reviewed on November 18, 2013